• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Tezspire (tezepelumab-ekko)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Tezspire (tezepelumab-ekko)

  • Profile

Profile

Contact Information

Contact: Amgen and AstraZeneca
Website: https://www.tezspire.com/

Currently Enrolling Trials

    Show More

    General Information

    Tezspire (tezepelumab-ekko) is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ). 

    Tezspire is specifically indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

    Tezspire is supplied as an injection for subcutaneous administration. The recommended dosage of Tezspire is 210 mg administered subcutaneously once every 4 weeks. If a dose is missed, administer the dose as soon as possible. Thereafter, the patient can continue (resume) dosing on the usual day of administration. If the next dose is already due, then administer as planned.

    Mechanism of Action

    Tezspire (tezepelumab-ekko) is a monoclonal antibody IgG2λ that binds to human thymic stromal lymphopoietin (TSLP) and blocks its interaction with the TSLP receptor. TSLP is a cytokine mainly derived from epithelial cells and occupies an upstream position in the asthma inflammatory cascade. Airway inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes, ILC2 cells) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in airway inflammation. Blocking TSLP with tezepelumab-ekko reduces biomarkers and cytokines associated with inflammation including blood eosinophils, airway submucosal eosinophils, IgE, FeNO, IL-5, and IL-13; however, the mechanism of tezepelumab-ekko action in asthma has not been definitively established.

    Side Effects

    Adverse effects associated with the use of Tezspire may include, but are not limited to, the following:

    • pharyngitis
    • arthralgia
    • back pain

    Clinical Trial Results

    The FDA approval was based on results from the PATHFINDER clinical trial program, which included the pivotal NAVIGATOR Phase 3 trial. The multicenter, randomized, double-blind, placebo-controlled trial enrolled 1,061 patients (12 to 80 years of age) with severe, uncontrolled asthma. Patients were randomly assigned to receive tezepelumab (210 mg) or placebo subcutaneously every 4 weeks for 52 weeks. The primary endpoint was the annualized rate of asthma exacerbations over a period of 52 weeks. This endpoint was also assessed in patients with baseline blood eosinophil counts of less than 300 cells per microliter. The annualized rate of asthma exacerbations was 0.93 with tezepelumab and 2.10 with placebo. In patients with a blood eosinophil count of less than 300 cells per microliter, the annualized rate was 1.02 with tezepelumab and 1.73 with placebo.

    Approval Date: 2021-12-01
    Company Name: Amgen and AstraZeneca
    Back to Listings

    Upcoming Events

    • 15Sep

      Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

    • 21Sep

      The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

    • 16Oct

      WCG MAGI's Clinical Research Conference 2022 West

    • 16Nov

      17th Annual FDA Inspections Summit

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Options-360x240.png

      Cancer Patients Signal Interest in Less Travel, More Remote Trial Options

    • SurveywBlueBackground-360x240.png

      New Study Shows Trends in Funding, Racial Balance Amidst COVID-19

    • Complexity-360x240.png

      Rising Trial Complexities Create More Payment Problems, Frustrations for Sites

    • Challenge-360x240.png

      BYOD Trials Growing in Popularity, But Unique Tech Challenges Remain

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing